Page 3 - ஸ்டிபேல் நிக்கோலஸ் யூரோப் வரையறுக்கப்பட்டவை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Anna Dunphy / Paul McManus / Louis Ashe-Jepson     GENinCode plc is engaged in the risk assessment, prediction and prevention of cardiovascular disease ( CVD ). CVD is the leading cause of death worldwide accounting for approximately 18 million deaths annually. The Company s products and technology have been developed with the aim of predicting the onset of CVD and providing a personalised treatment pathway for patient management. Its products have been the subject of clinical studies on over 75,000 patients to assess and predict the onset of CVD.   The Company was incorporated in September 2018 to acquire the assets, intellectual property and know-how of the Ferrer inCode and Gendiag.exe businesses, which were then part of Grupo Ferrer Internacional S.A., a large Spanish multinational private pharmaceutical and healthcare company. The technology and products acquired included Cardio inCode®, Lipid inCode®, Thrombo inCode® and Sud

United kingdomPaul folgerPaul foulgerGrupo ferrer internacionalStifel nicolaus europe limitedInvestor meet companyMatthew wallsNicolaus europe limitedSole brokerPaul mcmanusஒன்றுபட்டது கிஂக்டம்பால் போள்கேர்பால் கறைபடிந்தவர்க்ரூபொ ஃபெரர் உள்ஸ்டிபேல் நிக்கோலஸ் யூரோப் வரையறுக்கப்பட்டவைமுதலீட்டாளர் சந்திக்க நிறுவனம்